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Healthcare systems, as we know them, currently are evolving. The technological adjustment introduced by ICT systems dramatically has altered the way players, citizens, patients, clinicians, care providers, policymakers, governments, 
vendors, and suppliers interact. Privacy and confidentiality, personal data, and 
data protection issues are becoming highly relevant when discussing eHealth in its 
European legal and regulatory context.
  
Legal certainty is a prerequisite for businesses to invest in innovation, and for 
providers and users to take up new products and services. As long as the eHealth 
market is characterised by lack of regulation and legal certainty, barriers to the 
progress of eHealth will persist. 
The added value of eHealth is about developing a concerted and focused prospective 
approach of regulatory and other policy instruments to allow a varied set of 
technologies and innovative business models to rapidly meet demand and to benefit 
from the mobilising effect generated. 
Key to the success of the eHealth initiative is a debate at regional and national 
level concerning the conflicts about whether and to what extent the current 
legislation regarding eHealth interferes with public health policy. Legal liability and 
jurisdictional certainty are at the heart of this discussion, as well as cross-border 
provision on healthcare. The aim of this booklet is to present an overview of how the 
current EU-level registration can meet demands of regulating the emerging eHealth 
markets of Europe.
I hope that this booklet ‘Legally eHealth; Putting eHealth in its European Legal 
Context,’ can act as guidance for all players in the European health sector. 
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The term eHealth, although now quite current in Europe 
and, indeed, throughout the world, still is rather new, 
making its fi rst appearances in the scientifi c and policy 
literature around 1999. Its predecessors, however, date 
back to the 1960s when the concepts of health informatics 
and bio-medical computing began to occupy the minds of 
academic physicists, mathematicians, and medics. 
Th e 960s and 970s saw the development of computing 
technology for mathematical modeling applied to the 
healthcare setting, along with highly specialized, tailor-
made programmes for complex medical models. Th e 
early 990s saw the beginnings of the IT revolution, which 
took us from the back roads to the super highway. With 
the development of Internet technology, eHealth became 
a potential reality not only for healthcare practitioners 
but for every citizen. 
It was, however, not until the late 990s that layers and 
administrators began to question the extent to which 
existing legislation was suffi  cient to cover the use of 
eHealth tools in the provision of healthcare to citizens. 
Over the past decade, a number of articles, reports, 
and studies have established that the use of ICTs in 
healthcare does raise a number of legal questions, but few 
have looked, in detail, at the extent to which European 
legislation could provide good answers.
 
Th e Legally eHealth Report, therefore, seeks to examine 
some keys of the legal questions raised by the adoption of 
eHealth tools in healthcare. It looks at how EU legislation 
on data protection, product and services liability, and 
trade and competition law applies. 
In considering the law of privacy, the report examines 
the European Directives on Data Protection Directive, 
Privacy in Electronic Communications, as well as the 
European Convention of  Human Rights against the 
backdrop of a number of scenarios exploring data 
transfer for the  purposes of better care provision both 
across European and international borders, as well as for 
commercial purposes.
Th e report also addresses the vexed issue if liability 
eHealth goods and services, covering both simple 
eCommerce-like health services transacted over 
Websites, as well as much more complex issues such as 
multiple and split liability for services provided through a 
series of co-operating providers is also explored. Finally, 
noting that eHealth is a signifi cant, emerging European 
industry, the Legally eHealth report questions the extent 
to which European trade and competition law might 
apply to eHealth.
Th e overall objective of the report is to widen the audience 
of legal questions in eHealth since, until these issues are 
tackled head-on in real cases, we will not begin to change 
the legal landscape in order to provide fertile ground for 
new developments. eHealth is not just about technology, 
but about changing the everyday practice of healthcare 
for every healthcare professional and every patient.  
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The concept of eHealth and its reality in daily medical 
practice fundamentally challenges our understanding of 
the practice and regulation of healthcare in terms of the 
relationship between practitioner and patient, between 
practitioner and institution, as well as between institutions, 
between practitioners and institutions on one hand 
and, on the other hand, bodies involved in the funding 
(social security) and monitoring (public health control) of 
healthcare.
In the traditional model, patient access to the healthcare 
delivery system has been limited to predetermined 
points of entry, such as through a primary care physician. 
From the entry point, the patient’s progress through the 
system has been relatively linear and oft en dictated by 
the health system’s reimbursement processes. Similarly, 
processes, such as diagnosis, treatment, and care, have 
involved physical presence and personal interaction 
between providers and patients. Of course, such physical 
presence requires some sort of identifi cation (i.e., lack of 
anonymity). 
eHealth, however, is premised on a fundamentally new 
patient experience that is unconstrained by familiar 
points of entry and structures or traditional channels for 
delivering information or care. For one thing, anonymity 
or pseudonymity can be preserved much more easily. 
Not surprisingly, therefore, the eHealth revolution has 
brought about as many serious implications for healthcare 
regulators and lawyers as for medical professionals.
Although policy makers have noted at both the European 
and national level that a lack of legal certainty about the 
use of eHealth tools and services exists, little has been 
done to study the issue in detail. Certain projects,

 
funded under the Framework Programmes, have 
looked at the general legal issues concerning the use of 
information society technologies (IST), while others have 
included work packages looking at the legal aspects of a 
particular technology or application.
2
 Others have looked 
at one particular issue, such as confi dentiality, in greater 
detail.
3
 It would seem, however, that little work has been 
undertaken to date to look across the range of legal issues 
relevant to the use of IST tools and services in healthcare 
and to draw conclusions about the regulatory needs that 
may exist.
In order to fi ll this gap, a study
4
 was conducted between 
January 2006 and May 2007 to investigate the extent to 
which European Community legislation, contained in 
various Directives, provided suffi  cient legal certainty 
to allow eHealth to prosper in Europe. Th is current 
report draws together the results of that study, focusing 
particularly on the challenges of compliance with rules 
on data protection and privacy, questions of product and 
services liability, and on the role of EU competition law 
on the development of the eHealth industry within the 
European internal market.
Th e objective of this report is to provide the reader 
with an overview of the extent to which current EU-
level legislation can meet the demands of regulating the 
nascent eHealth markets of Europe. It does not purport 
to give legal answers, but rather to give the reader a basis 
from which to examine your own eHealth situations and 
to arm you with appropriate questions to ask within the 
relevant national or regional legislations.
Introduction
see for example:  Legal IST-  FP6-IST  
see for examples: NEXTGRID – FP6-IST or  EUROGENTEST – FP6-
LIFESCIHEALTH and FP5- GEMSS
see for example: EUROSOCAP – Quality of Life Programme (FP5)
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eHealth is a very broad term and encompasses many 
concepts. For this study, we have taken the term to 
include the wide range of information technology-based 
applications found in hospitals and primary care settings. 
Th ese include administrative tools, such as hospital 
information systems (HIS), summary records, and 
discharge letters; clinical technical applications, such as 
picture archiving and communications systems (PACS); 
as well as clinical support systems, such as operating 
theatre systems, decision support systems (DSS), and 
systems linking institutions such as General Practitioners 
Systems; and electronic prescribing systems linking 
general practitioners with pharmacies (eRx). At the heart 
of our eHealth world is the elusive holy grail of eHealth – 
the fully interoperable cradle-to-grave Electronic Health 
Record.
 
Th e stakeholders in the world of eHealth may be 
classifi ed into four groups of actors: Citizens and patients; 
clinicians and care providers; payers, policy makers and 
governments; and vendors, suppliers, and commercial 
partners. All four groups have highly signifi cant but 
not always equal roles to play in healthcare. We look, in 
particular, at the tensions that can arise between clinician 
and patient with respect to privacy and confi dentiality 
or between government and vendor with respect to 
competition in the healthcare market.
While a wide range of legal issues are relevant to eHealth, 
ranging across contract law, employment law, and even 
criminal law, it was felt that three areas of law are particularly 
diffi  cult to interpret in the context of eHealth. Given that 
eHealth intrinsically is dependent upon the collection and 
sharing of patient data, it is important to examine the extent 
to which data protection and privacy laws impact upon 
its practice (see for example the discussion on Directive 
95/46/EC on Data Protection). Similarly, since eHealth 
frequently will be used in order to facilitate collaboration 
between diff erent care providers funded from diff erent 
budgets and with varying levels of responsibility to the 
patient, it is important to examine to what extent current 
rules on liability for goods and services cover the provision 
of healthcare using eHealth tools (see for example the 
discussion on Directive 97/7/EC on Distance Contracting). 
Finally, in order to allow eHealth to prosper, it is important to 
ensure that trade and competition law, as it currently stands in 
Europe, does not pose any problems for this nascent industry. 
Accordingly, we also look at the implications of EU-level 
competition law (see for example the discussion on Articles 8 
and 82 of the Treaty on the European Communities).
1Setting the scene: 
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2Processing 
Medical Data in eHealth
Data Protection, 
Confi dentiality and 
Security
Introduction
eHealth applications, whatever their nature, frequently 
will involve the processing of information relating to 
an identifi ed or identifi able patient. Such information 
legally is known as personal data and is subject to data 
protection legislation in the European Union. In Europe, 
such data are protected by legal rules found in a number 
of legal sources, the most important of which is the 
Directive on Data Protection (Dir. 95/46/EC), which 
now has been transposed into national data protection 
legislation across the EU.
Th e following pages provide a very quick overview of 
key aspects of the European Data Protection Directive. 
Th e full Directive can be downloaded at http://ec.europa.
eu/justice_home/fsj/privacy/ where each Member State’s 
national legislation transposing the Directive also is 
available. 
What is the purpose of the 
Data Protection Directive?
Th e primary purpose of the EU Directive on Data 
Protection (95/46/EC) is to protect the fundamental 
rights and freedoms of natural persons, which are real 
people, as opposed to legal persons or entities such as 
companies or societies. Within the legislation, such a 
natural person is referred to as a data subject – in other 
words, the person to whom the personal data relate. Th e 
Directive, however, has a further purpose: To allow the 
free movement of personal data within the European 
Union in the context of the internal market. On the one 
hand, its object is to protect the privacy of individuals 
while, on the other hand, it is to allow freedom of 
movement of data across the European Union in order 
that the internal market might prosper.  
To what types of data does 
the Directive apply?
In order to establish if data are covered by the Directive, 
one fi rst must ask if the data are such that they allow the 
identifi cation of a particular natural person. Second, 
is the data going to be processed by someone (a legal 
or natural person). Th us, the laboratory result of a 
blood sample test, giving the count of various markers 
in the blood, will be covered by this legislation if the 
identifi cation of the originator of the blood is possible 
using reasonable means. Th e Directive applies also if the 
laboratory results are stored with coded identifi ers, such 
as a patient number. Th e basic principle here is that if a 
piece of information can be linked to a person either by 
reasonably simple means, by or with the help of a third 
person, then the data is considered as identifi able and, 
therefore, in the scope of the Directive. If the information 
refers to a group, or if it is so complete or so unique as to 
make it applicable to only a very small number of people 
(e.g., disease profi le, age, gender, postcode, profession 
all held together), then the data could be classifi ed as 
identifi able even if no actual identifi er were used.  
Who has data protection 
duties?
Th e data protection rules are addressed primarily to the 
data controller – the person who decides the purpose and 
the means of the processing and who has the legal duty 
to ensure that data are handled appropriately. In most 
professional cases, this will be a senior staff  member who 
is named as the person responsible for data collection 
and storage by an organisation.
In the case of small companies or self-employed 
individuals (such as many General Practitioners), the 
data controller generally will be the person who has 
legal and tax liability for the organisation. It should be 
noted that organisations need not be businesses or legally 
constituted to be covered by the legislation; a disease 
self-help group will fall within the legislation and its data 
controller will be its president or other lead person.    
What are the main duties 
of a person who controls 
personal data?
Any personal data that the controller needs to process for 
the purposes of his or her professional activity must meet 
certain levels of quality, and must comply with diff erent 
principles concerning data collection and processing.
Th e data must be collected for specifi ed, explicit, and 
legitimate purposes. Th is principle requires that, prior 
to processing personal data, the controller has to defi ne 
clearly and precisely the purpose(s) for which the data 
are to be processed. Moreover, the processing should be 
transparent. Th e data controller will, therefore, have to 
provide the relevant national data supervisory authority 
and the data subject with certain information regarding 
the processing, and may only process the data for the 
purposes for which it was collected.
 
Th us, a doctor who may share patient identifi able data 
with another doctor for the purposes of treating the 
patient may share that same information with another 
healthcare professional for the purpose of conducting 
medical research if that purpose originally was given as 
one of the fi nal uses of the data. It also would apply if this 
is compatible with the latter (especially if the data subject 
has given his or her consent to the communication) or if 
appropriate safeguards are met for processing personal 
data for medical research viewed as a scientifi c purpose 
(i.e., reasonable steps are taken to hide the true identity 
of a data subject). If the personal data are anonymised 
by the doctor, there is no problem to communicate the 
anonymous data to a third party for scientifi c purposes, 
including medical research safe for other special rules in 
National Law (i.e., medical secrecy). Also, they must be 
processed fairly and lawfully so that if a researcher collects 
data in order to carry out a specifi ed research project, he 
or she may not collect and process other data that are not 
necessary for that particular study but might be useful at 
some later date. Th e controller also must ensure the data 
are kept up-to-date while they are needed, and not kept 
longer than necessary. 
 
What rights do data 
subjects have? 
Data protection law not only gives duties to data 
controllers, but also rights to data subjects, such as 
patients. Laws in EU countries grant access rights to all 
data subjects to data held about them, which allows them 
to request specifi c information about their own personal 
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data; the right to ask for data to be rectifi ed when they are 
incomplete or inaccurate; and, under some conditions, 
the right to object to the processing. On the basis of these 
duties, most EU countries have introduced legislation 
that allows patients to access their medical records and 
to demand a rectifi cation of those records.
Are medical data treated 
diff erently from other data?
All the principles described above are general principles 
that may alter very slightly when the data are regarded 
as especially sensitive. Data concerning a person’s health, 
religion, trade union activity, as well as data revealing 
racial or ethnic origin and judicial information, are 
amongst the data regarded by the Directive as especially 
sensitive and, therefore, subject to special rules. For 
this reason, data that are capable, by their nature, of 
infringing fundamental freedoms or privacy of the data 
subject normally should not be processed.
Th e ban on processing sensitive or medical data aims 
to ensure the fundamental rights and freedoms of 
the data subject regarding the processing of his or her 
medical data. Th e ban is, of course, not absolute, so all 
EU countries hold, by principle, that medical data may 
be collected or processed only for certain purposes and 
following certain guidelines, including notably: 
• Th at the explicit informed consent of the data 
subject is obtained
• To protect the vital interest of the data subject 
or of another person when the data subject is 
physically or legally incapable of giving consent
• For the purposes of preventive medicine, medical 
diagnosis, the provision of care or treatment, 
or the management of healthcare services, if 
the data are processed by a health professional 
subject to the obligation of professional secrecy 
or by another person also subject to an equivalent 
obligation of secrecy.
Introduction to case vignettes
In order to place the general overview of the principles 
of EU data protection in its eHealth context, a series of 
fi ctional case vignettes have been constructed on the 
basis of reported case histories. Th ese outline the way in 
which data protection rules might be applied in practice. 
Th e case vignettes are not real cases as such, but are 
informed by reports of real cases and are grounded in 
medical practice reality. 
CASE VIGNETTE 1: SECOND MEDICAL OPINION FROM 
A COLLEAGUE IN ANOTHER EU COUNTRY
Wilhelm Wolfgang, 50, a building construction 
manager from Stuttgart, has suff ered from multiple 
allergies both respiratory and dermatological, since 
he began working on construction projects at age 8. 
Other than the recurrent allergies, Wilhelm, a non-
smoker, generally has been in good health.
Unfortunately, his most recent routine X-ray revealed 
some suspicious areas on the upper right lung. 
Wilhelm’s specialist, Dr. Willy Weiss, would like to ask 
a second opinion regarding the images and the case.
He identifi ed Prof. Alexander Artemis, a world expert 
of pulmonary imaging in the detection of rare lung 
diseases, located in Greece. 
Dr. Weiss wonders whether the digital X-ray images 
can be transferred safely and securely to Prof. Artemis. 
A conversation with Prof. Artemis reassures him on 
that score. In addition, Prof. Artemis is quite happy to 
provide his analysis free of charge. 
Wilhelm is hoping that Prof. Artemis can provide 
his opinion from a distance, although he is willing 
to fl y over, if expenses can be reimbursed. Wilhelm 
thinks that two opinions give more credibility to the 
decisions that will follow. 
Th e legal analysis
In this case, we see a typical doctor-patient relationship. 
However, since the story includes the transfer of medical 
data, we can use it to look carefully at the legal duties 
of doctors wishing to collaborate, over a distance, using 
standard tools for sharing electronic medical reports and 
records.
In order to establish which rules apply to the proposed 
transfer of data from Germany to Greece, a number of 
questions must be asked:
HAVE THE DATA BEEN LAWFULLY COLLECTED?  
Th e answer would seem to be positive since Wolfgang 
has agreed to the X-ray and to its possible transmission 
to Prof. Artemis. Given that the data are medical data, Dr 
Weiss will be subject to the special rules concerning the 
processing of sensitive data. 
IS IT LEGITMATE TO PROCESS THE MEDICAL DATA?
Again, the answer would seem to be yes since Dr. Weiss 
processes Wilhelm’s medical data as a registered medical 
practitioner and, as such, is entitled to collect and 
process such data as it is needed for medical diagnosis 
and the provision of care or treatment to Wilhelm. 
In this case, the medical data have to be processed by 
a health professional subject under national law or 
rules established by national competent bodies to the 
obligation of secrecy or by another person also subject to 
an equivalent obligation of secrecy. 
CAN THE MEDICAL DATA BE SENT TO ANOTHER 
COUNTRY? 
Yes. Prof. Artemis is a medical doctor, in a European 
Union country, and the data is communicated for the 
purposes of providing medical diagnosis. Note, however, 
that Dr Weiss has a legal duty to ensure that Prof. 
Artemis and his hospital provide suffi  cient guarantees on 
technical and organisational security measures. 
3Data processing Case Vignettes
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4
WHAT LEGAL DUTY DOES THE THIRD-PARTY DATA 
RECIPIENT HAVE?
Prof. Artemis will be processing the personal data on 
behalf of Dr. Weiss and will be therefore, considered as 
a data processor who must act only on instructions of 
Dr. Weiss. He must take the appropriate technical and 
organisational measures of protection.
CASE VIGNETTE 2:  PROCESSING OF MEDICAL 
RECORDS OUTSIDE THE EU
Dr. Caroline Carrington is a general practitioner who 
recently arrived in a busy group practice, in Loch 
Harlow, Lannockshire, Scotland. Dr. Carrington 
replaced Dr. Charles Cramer, who retired in May 
2006, inheriting his carefully handwritten records. 
Dr. Carrington wanted to switch to digital records 
as quickly as possible, before multiplying her own 
additions to the fi les. 
Dr. Carrington’s problem on how to digitalise Dr. 
Cramer’s fi les seemed to fi nd a providential answer 
when she opened an envelope from Soft Support Ltd, 
multinational soft ware specialists. Inside there was 
a prospectus indicating that International Medical 
Records Coordinators (IMRC) Ltd., a division of 
Soft Support, would be stopping in Loch Harlow over 
the summer to provide record scanning services.
Founded by Dr. Gautam Gandhi, a practicing 
physician in the UK, IMRC had been sold to 
Soft Support in 2005. IMRC’s business was based on 
Dr Gandhi’s connections between the UK and India. 
IMRC scans patient records in a mobile unit stationed 
outside British practices, then sends them to IMRC 
offi  ces in India for data entry to populate a database 
held in the practice. 
Dr. Carrington wonders if she can make use of the 
off er of IMRC Ltd.
Th e legal analysis
IS IT LEGALLY ACCEPTABLE TO DIGITIZE PAPER 
RECORDS?
Th e legal question here is whether such processing of the 
patients’ medical data is compatible and necessary with 
the initial purpose for which the data were collected, 
i.e., treating patients. It would seem to be the case since 
digital records will allow Dr. Carrington to treat her 
patients more effi  ciently. 
CAN DIGITIZATION OF PAPER RECORDS BE 
OUTSOURCED DOMESTICALLY?
Th e legal duty of care to the patient, respect to privacy, 
and confi dentially remains with Dr. Carrington, or with 
the practice, which legally are designated as the data 
controllers. IMRC would be acting as a data processor 
for Dr. Carrington, who will have to ensure that IMRC 
can provide suffi  cient guarantees on technical and 
organisational security measures and to sign a contract 
to that eff ect.
CAN  FURTHER PROCESSING BE OUTSOURCED 
OUTSIDE THE EU?
IMRC intends to do more than simply digitise records. 
Once scanned, the digitised medical fi les will be sent 
to India (thus outside the European Union) in order 
to populate a searchable database of medical records 
located in the UK. Th e transfer of data to India could 
only be permitted if India ensures an adequate level of 
protection. Today, India does not seem to ensure such 
level of protection. Such transfer of data to India would 
be permitted either on the basis of the unambiguous 
consent from the patient or on the basis of a contract 
signed between Dr. Carrington and the recipient of the 
personal data, imposing on the latter the conditions 
of the data processing based on the standard contract 
terms available from the European Commission Th e 
recipients of the communication have to be subject to 
confi dentiality rules equivalent to those incumbent to 
health care professionals. Again, to ensure a fair data 
processing, Dr. Carrington or the practice should inform 
the patients that the digitalized medical records have 





As consumers of goods and services, we expect the law 
to protect us from potential harm from poor goods or 
services by having strong requirements of high quality 
and to provide us with adequate means for redress if we 
are harmed in some way. Th e object of this section is 
to investigate how far, at a European level, the existing 
legislation on consumer protection is adequate to protect 
users of eHealth systems, tools, and services. 
It is clear that the provision of eHealth products, systems, 
and services must comply with certain levels of quality. 
Diff erent legal texts have been agreed upon to provide 
consumers with legal guarantees for any damages 
resulting from sub-standard products or services. Th e 
legal texts do not apply exclusively to eHealth, but 
instead are applied with a general context of service 
provision and product delivery, whether by traditional or 
via electronic means. We will explore the range of EU-
level consumer protection legislation that could apply 
to eHealth systems and services, exploring issues such 
as dissemination of information via Websites, electronic 
advertising, contracting online, and delivery of products 
or services. 
Th e concept of the eHealth product is sometimes 
diffi  cult to understand because, in practice, most eHealth 
products either will be soft ware packages and interfaces 
(electronic health record, decision support tool) or they 
might be hardware devices with embedded soft ware 
(radio frequency identifi cation location trackers for 
locating people and objects; remotely controlled medical 
devices). We take a broad defi nition of an eHealth 
product or service to include anything sold to a medical 
practitioner or directly to a consumer that uses an 
Internet-enabled component to deliver benefi t. As such, it 
might be an electronic record to be used by the doctor, or 
a monitoring device that includes a Web-based interface. 
It might even be just a simple health information portal. 
Pure medical devices, such as blood pressure monitors, 
are excluded from our defi nition unless an ‘e’ interface 
is used. 
It is important to note that at present, no specifi c 
legislation exists at an EU level that specifi cally targets 
such eHealth services and products. Legally, these 
products will be covered by a range of legislation. 
 
It is important to note that at present, no specifi c 
legislation exists at an EU level that specifi cally targets 
such eHealth services and products. Legally, these 
products will be covered by a range of legislation. 
Does the sale of consumer 
goods legislation apply to 
eHealth goods and services?
At a most simple level, the sale of any product – be it 
eHealth or any other – will be covered by standard 
contracts for sale of goods. Th us, if the eHealth product 
fails to arrive or arrives late, the standard clauses in the 
contract will apply. Th ese allow the purchaser to pay less 
or to return the goods. Similarly, national legislation 
based on the EC general product liability directives 
(Directive 200/95/EC and Directive 999/34/EC), 
ensures that the purchaser has redress if consumer goods 
are not fi t for the purpose sold, as well as the relevant 
national legislation based on Directive 999/44/EC on 
the Sale of Consumer Goods. 
According to these EU directives, when eHealth tools are 
sold as consumer goods, the seller must deliver goods 
Buying, selling, and 
using eHEALTH Tools and Services
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How will consumers and 
professional users be 
protected if an eHealth 
product or services causes 
damage?
Directive 85/374/EC on Defective Products will apply 
to eHealth products in the same way as it applies to 
any other product sold on the European market. This 
Directive aims to ensure a high level of consumer 
protection against damage caused to health or property 
by a defective product. It also aims to reduce the 
disparities between national liability laws, which distort 
competition and restrict the free movement of goods. The 
Directive establishes the principle of no-fault liability for 
damage caused by a defective product and, as a result, the 
producer, importer, or supplier will be liable and must pay 
compensation for damage caused to persons or property 
resulting from a defect. The injured person does not have 
to prove that the producer was at fault or negligent, but 
simply needs to prove that damage arose, that a defect in 
the product exists, and that there is a causal relationship 
between defect and damage (this is known as the concept 
of ‘strict liability’). 
For example, if defective software used to drive an infusion 
pump causes an incorrect dosage to be administered, and 
the patient is caused harm, then the patient will not need 
to prove the fault of the manufacturer of the software. 
He would just have to prove that he was injured, not the 
fact that the software does not provide the safety that a 
patient is entitled to expect. Nor does the patient have to 
show a link between the dosage error and the injury.
However, in order to strike a reasonable balance between 
the interest of the consumer and the need to encourage 
innovation and technological development, there are 
some rules protecting the producer. Therefore, the 
period of liability has been limited to three years from the 
moment the consumer becomes aware of the damage, the 
defect, and the identity of the producer. And the liability 
is limited to ten years after the producer has placed the 
product on the market.
What about liability for an 
eHealth service?
An eHealth service might be passive, such as delivering 
general medical information through a Website, or might 
be active in giving medical advice or specific decision 
support to clinicians, or might involve the collection of 
biomedical data for remote monitoring by a clinician. 
Such a service might conceivably cause damage to 
someone relying on the service. A citizen might follow 
bad advice and fall ill, or even die; a clinician might 
follow the recommended procedure after using a decision 
support tool and might harm a patient; or a remote 
monitoring service might fail to transmit relevant data, 
thereby putting a patient’s life at risk.
In many such cases, a causal link will exist between the 
harm suffered and a defective product. Thus, if an error 
exists in decision-support software, the doctor who relied 
on the software would have a claim based in Council 
Directive 85/374/EEC, as described above.
There currently is no general European harmonisation 
of liability rules for services in which no defect can 
be found in a device. Therefore, liability for services 
is governed by ordinary rules of law applicable in the 
Member States. An exception to this may exist if a service 
is supplied wholly by electronic means, in which case the 
eCommerce Directive (Directive 2000/3/EC) might 
apply. These issues are further considered below, looking 
at questions on health-related Websites and health-
related eCommerce.
What about eHealth 
services  provided to 
patients via the Internet?
Any eHealth services provide via the Internet will be 
subject to the national legislation derived from the 
eCommerce Directive if they meet the qualities of an 
information society service. That is any service normally 
provided for remuneration, at a distance, by electronic 
means, and at the individual request of a recipient 
of services (such as through the Internet). It covers 
services between enterprises or between enterprises and 
consumers, which are paid directly from the recipient 
(online transactions) or those financed by indirect 
means, such as advertising income or sponsoring. 
Activities, which by their very nature, cannot be carried 
out at a distance and by electronic means, such as 
medical advice requiring the physical examination of a 
patient, are not information society services. When the 
physical examination of the patient is not necessary, then 
the service may be considered as information society 
service, such as:
•  Websites of doctors promoting their activities
•  Online selling of medicines (ePharmacy)
•  Online advice that does not require the physical 
examination of the patient if a fee is paid or if it is 
financed by advertising or sponsorship
•  Online databases of information accessible for 
medical professionals or consumers if a fee is paid 
or if it is financed by advertising or sponsorship 
(even indirectly).
as described in the contract of sale. Moreover, when a 
commercial guarantee exists, the seller or producer who 
has offered the goods for sale legally will be bound to 
that guarantee, as well as to the associated advertising. 
Any such commercial guarantee will have to be made 
available in writing (or another durable medium, such as 
an e-mail) and will have to contain certain information. 
Anyone selling an eHealth product as a consumer good 
would, therefore, have to comply with these rules and, 
conversely, a purchaser of an eHealth product would 
have redress under them.
Is there general product 
safety legislation that 
applies to eHealth goods 
and services?
The General Product Safety Directive (200/95/EC) 
imposes a general safety requirement for any product 
put on the market for consumers. In addition, they 
must provide consumers with relevant information 
enabling them to assess the risks inherent to the product, 
particularly when it is not obvious, and take appropriate 
actions to avoid these risks (withdrawal from the market, 
warning to the market consumers, recall products already 
supplied, etc.). To assist consumers, national authorities 
have established systems to monitor product safety and 
to take appropriate measures to protect consumers. 
Such a system also exists at the EU level in RAPEX, 
a European rapid alert system for dangerous non-
food products, which ensures that information about 
dangerous products identified within the Member States 
is quickly circulated between the Member States and the 
Commission. To date, no eHealth products have been 
listed in RAPEX, but as consumer products in eHealth 
become more common, this will serve a useful purpose 
in the eHealth sector.
Could eHealth applications 
and tools be considered 
medical devices?
Any eHealth device placed on the market, which is 
designated by its manufacturer as a medical device, 
will be subject to the specific additional rules regarding 
medical devices. The medical devices sector is covered by 
three directives, covering a wide scope of products. The 
first Directive, (90/385/EC), deals with active implantable 
medical devices, the second Directive, (93/42/EC), 
deals with medical devices in general, while the third 
Directive, (98/79/EC), deals with in vitro diagnostic 
medical devices.
The General Directive (Dir. 93/42/EC) concerning 
medical devices aims to safeguard the health and safety 
of patients and users by harmonising the conditions 
for placing medical devices on the market and putting 
them into service. The medical devices must be designed 
and manufactured in such a way that their use does not 
compromise the safety and health of patients, users, and 
other persons when properly installed, maintained, and 
used in accordance with their intended purpose. If a 
Member State notes that a medical device conforming 
to the Directive compromises the health and/or safety 
of patients, users, or, where applicable, other persons, it 
shall take all appropriate interim measures to withdraw 
such devices from the market or prohibit or restrict their 
being placed on the market or put into service.  
The Directive on In Vitro Diagnostic Medical Devices 
provides that such devices may be placed on the market 
and put into service only if they comply with some 
requirements. This obliges Member States to monitor 
the security and the quality of these devices and to take 
appropriate measures to withdraw dangerous devices 
from the market. Where a medical device is used to 
dispense a medicinal product, Directive 200/83/EC on 
Medicinal Products for Human will require that any 
such compound dispensed by the device is covered by 
a marketing authorisation issued by a national oversight 
authority. 
Although early eHealth devices frequently were not 
designated as medical devices, the growing market in 
personal health monitors or any medical support tools, 
such as wearable and implantable monitors, will ensure 
that more and more such eHealth tools are designated 
as Medical Devices so that this legislation will grow in 
importance. 
Finally, it should be noted that national, international, 
and European standards bodies are developing standards 
that apply to eHealth products. Examples include the 
European Standards Agency (CEN) standard for EHRs 
(CEN ENV 3606), the American HL7 standard for EHR, 
or, indeed, the industry standard for the communication of 
medical digital images (DICOM).
5
 While these standards 
are not legally binding, they do provide a baseline against 
which disputes about the quality of an eHealth product, 
covered by a standard, might be assessed. 
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information is not stored for any period longer than is 
reasonably necessary for the transmission.
Caching is an information society service consisting 
of the transmission in a communication network of 
information provided by a recipient of the service. When 
providing such caching services, the service provider is 
not liable for the automatic, intermediate, and temporary 
storage of that information, performed for the sole 
purpose of making more efficient the information’s 
onward transmission to other recipients of the service 
upon their request.
When providing these three information services (Mere 
Conduit, Caching, or Hosting), providers can not be 
obliged to monitor the information that they transmit 
or store, nor to actively seek facts or circumstances 
indicating illegal activity.
Are there any special rules 
for contracts for eHealth 
goods or services?
Much eHealth business necessarily will involve the 
drawing up of contracts. On the whole, normal national 
contract law will apply, transposing where applicable 
EU-level directives. The agreement of eHealth contracts 
could occur for the delivery of eHealth products or for 
the provisioning of eHealth services. The latter includes 
the online provision of medical care, such as tele-
monitoring.  
Generally, such a contract will be governed by normal 
national contract law, being simply a contract for service. 
Where such a contract is made between parties in different 
European countries, the usual rules about cross-border 
contracting will apply. This means that the contracts will 
be drawn up under the law of the state in which either 
the purchaser or provider resides. A number of legislative 
instruments at the EU level already have been adopted 
to ensure that parties to such contracts can know, in 
advance, under which jurisdiction any eventual dispute 
will be resolved. The Brussels Regulation (Regulation 
44/200/EC) concerning jurisdiction and the recognition 
and enforcement of judgments in civil and commercial 
matters, and the 980 Rome Convention on the law 
applicable to contractual obligations, are the reference 
points for EU-level contracts.  
A further area of legislation could apply to a contract 
concluded by electronic means. Directive 997/7/EC 
on Distance Contract imposes on the supplier a duty 
to provide the recipient with written information (or 
another durable medium such as an e-mail or online 
information) prior to the conclusion of the contract 
concerning the supplier’s identity, the product or service, 
and the price. In such contracts, the rules on electronic 
signatures also will apply (Directive 999/93/EC). This 
provides that national-level legislation must ensure a 
legal equivalence between the handwritten signature 
and advanced electronic signatures based on a qualified 
certificate. A simple form of eSignature, such as a scanned 
handwritten signature, may be used, but if a dispute 
arises, experts would need to advise on the evidence 
value of this signature. The advantage of the advanced 
electronic signature is that, in the context of a trial, this 
type of signature is directly considered as having the 
same evidence value as the handwritten signature.
What duties and rights 
arise from an eHealth 
services provided via the 
internet? 
A doctor or other party running a health-related Website, 
whether it is a passive information site or one supplying 
services, will have to inform the users of his identity, 
address, and VAT number, if applicable. If the service is 
provided by a doctor, or other profession subject to rules 
of professional registration, the full registration details 
applicable in the country of registration also must be 
provided. These information duties aim to enable the 
user of the Website (passive or active) to identify the 
service provider and to ensure transparency of activities. 
In essence, the purpose of these information duties is to 
allow users to know against whom they can seek redress 
if they should need to do so. 
This principle of transparency of provider of site is 
included within the Commission’s Communication 
on Quality Criteria for Health-related Websites (COM 
2002/667), which seeks to increase the reliability of health-
related Websites and also include other quality criteria 
that health-related Websites should comply with, such 
as transparency of the purpose of the Website, respect 
of privacy, accessibility adapted to the target audience, 
etc. Those quality criteria may serve as reference in the 
development of quality initiatives for health-related 
Websites. 
If a health-related Website includes any type of 
communication promoting goods, services, or the 
image of a company, the eCommerce Directive imposes 
further duties that require that any such commercial 
communication should be clearly identifiable as such 
and the person on whose behalf the commercial 
communication is made must be clearly identifiable as 
well. The purpose is to avoid any confusion between 
advertising and any other type of information. The 
eCommerce Directive does not replace other legal texts 
that impose particular rules or restrictions relative 
to advertisement concerning regulated professions, 
such as doctors or dentists. Therefore, the advertising 
of prescription-only medication still is prohibited on 
European-registered Websites (Directive 200/83/EC). 
However, given that direct-to-consumer advertising of 
prescription medication is permitted in the United States, 
many European citizens find American advertising on the 
Internet and buy directly from these American sellers.
If a health-related Website is offering services or products 
not covered by the ban on advertising of prescription-
only pharmaceuticals, further consumer protection laws 
will apply, notably those derived from Directive 2005/29/
EC on Unfair Business to Consumer Practices. This 
includes, for example, a ban on promoting a medicinal 
service or product as 00% effective, and without any side 
effects, when the trader must reasonably know that the 
tests made cannot completely exclude the possibility of 
all potential side effects. 
Which countries rules 
apply to services offered 
via the Internet? 
In general, the rules of the country in which the service 
provider is registered will apply. That is why information 
on the service provider must be given on the Website. 
This is known as the country of origin principle, which 
provides that the law applicable to an eCommerce 
activity will be the law of the country in which the service 
provider is established. For example, if an electronic 
healthcare service provider, established in Italy, provides 
online information to doctors in different places in 
Europe, it will fall under Italian law. 
However, there are exceptions to the country of origin 
principle. Most notably, Member States have the right to 
derogate from this principle if, for example, it is necessary 
for the protection of public health. 
Does the Internet Services 
Provider (ISP) have any 
special duties?
The eCommerce Directive establishes a special 
exoneration system of liability for some categories of 
Internet intermediaries (mere conduit, caching, and 
hosting) in detailed circumstances. The “Mere Conduit” 
is an information society service consisting of:
• The transmission in a communication network of 
information provided by a recipient of the service or
• The provision of access to a communication 
network
When providing such “Mere Conduit” service, the service 
provider is not liable for the information transmitted. To 
benefit from this exemption, the provider has to comply 
with several cumulative conditions:
• The provider does not initiate the transmission
• The provider does not select the receiver of the 
transmission
• The provider does not select or modify the 
information contained in the transmission
The acts of transmission and of provision of access 
include the automatic, intermediate, and transient storage 
of the information transmitted insofar as this takes place 
for the sole purpose of carrying out the transmission 
in the communication network, and provided that the 
see http://www.openehr.org/standards/t_cen.htm 5.
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5Product and Services Liability 
Case Vignettes
Introduction
In order to place the general overview of the principles of 
product and services liability of the European Union in 
its eHealth context, a series of fi ctional case vignettes have 
been constructed on the basis of reported case histories. 
Th ese will outline the way in which the data protection 
rules might be applied in practice. Th e case vignettes are 
not real cases as such, but are informed by reports of real 
cases and are grounded in medical practice reality. 
CASE VIGNETTE 1:  BUYING A MEDICINAL PRODUCT 
ON-LINE
Ben Bemelmans, an 8-year old Belgian, is a keen 
Internet user, spending most of his waking moments 
online. Last summer, Ben’s stay at summer camp was 
marred by his tent-mates making fun of his snoring. 
Ben was determined to put an end to the problem 
without telling his family. 
Late one night, Ben Googled “snoring treatment” and 
found an advertisement for an international online 
pharmacy, off ering a one-week, over-the-counter 
(OTC) cure for snoring. Th e eff ect of the treatment 
was guaranteed to last a minimum of six months. Ben 
used his credit card to order the item.
Th e product, named HypnoNix, arrived at the 
Bemelmans’ home in Liège in only three days, despite 
the fact that the international pharmacy warehouse 
was situated on Cyprus. Ben was a little bit surprised 
to note that the product leafl et was in Greek, but the 
information on the Website in English was more than 
suffi  cient. In any event, Ben was very happy with his 
purchase, because he recorded his sleep between two 
and three in the morning and noted that he no longer 
snored.
However, one month into the treatment, Ben 
developed sudden and severe shortness of breath and 
nosebleeds. Wondering whether HypnoNix could be 
responsible for this, he returned to the Website and 
read the fi ne print. HypnoNix can induce a variety 
of respiratory ailments. Ben had not noticed that 
information the fi rst time around and wondered if it 




Ben thought he found the perfect solution to his snoring 
problem aft er reading an advertisement for HypnoNix on 
the Website of an international pharmaceutical company, 
which is established in Cyprus. In theory, he should have 
been cured for at least six months aft er the one-week 
HypnoNix cure. HypnoNix was delivered over-the-
counter and the product leafl et was written in Greek, a 
language Ben does not understand. Th e snoring stopped 
but, one month later, Ben developed breathing problems 
and nosebleeds. He returned to the Website, read the fi ne 
print, and discovered that HypnoNix could have side 
eff ects such as respiratory problems. He is not sure that 
this information was on the Website when he ordered the 
HypnoNix cure.
What went wrong in this case? To answer this question, 
we have to consider the diff erent regulations applicable 
to Ben’s situation. 
IS BUYING A MEDICINAL PRODUCT ON LINE SUBJECT 
TO ECOMMERCE LAW? 
Off ering an over-the-counter medication for snoring is 
an information society service, since it does not seem 
to require the physical examination of the patient. Note, 
however, that this is dependent on the drug not requiring 
a prescription to be sold, since in many EU countries, 
an online prescription may be made only where the 
doctor and patient have an existing relationship in which 
the doctor has previously met with the patient face-to-
face. In some countries, medical advice by electronic 
communication (e-mail or Website) is never permitted, 
even if such a relationship already exists.
We may assume that the service provider is established in 
Cyprus; hence Cypriot Law will apply to this eCommerce 
activity according to the principle of country of origin. 
Th is means that we need to establish that the service 
provider has complied with his duties as an information 
society service provider, principally that all the required 
information is provided: 
• Th e name of the service provider (the pharmaceutical 
company making HypnoNix, or the vendor)
• Th e geographic address at which the service provider 
is established, in this case Cyprus
• Details of the service provider, including its e-mail 
address, which allows it to be contacted rapidly and 
communicated with in a direct and eff ective manner
• Where the service provider is registered in a trade 
or similar public register, the trade register in which 
the service provider is entered, and his registration 
number or equivalent means of identifi cation
• Where the activity is subject to an authorisation 
scheme, such as the sale of pharmaceutical products 
and the particulars of the relevant supervisory 
authority
• Th e Value Added Tax number also should appear 
on the advertisement
• Th e price of the HypnoNix cure should appear on 
the Website and should indicate if it is inclusive of tax 
and delivery costs, as the product will be sent from 
Cyprus to Belgium.
DOES THE LAW ON DISTANCE CONTRACTING APPLY 
TO A THE PURCHASE OF A MEDICINAL PRODUCT 
ON-LINE? 
Ben purchased HypnoNix by a distance contract. 
Prior to the conclusion of this distance contract, the 
pharmaceutical company should have provided him with 
the following information: 
• Identity of the supplier and, if payment in advance is 
required, supplier’s address
• Th e main characteristics of HypnoNix
• HypnoNix price, including all taxes
• Delivery costs
• Arrangements for payment and delivery
• Existence of a right of withdrawal
• Th e period for which the off er or the price remains 
valid.
If Ben had chosen to exercise his right of withdrawal, the 
pharmaceutical company should have repaid him the 
price within thirty days.
DO GENERAL RULES ON CONSUMER GOODS APPLY 
TO THE SALE OF MEDICINAL PRODUCTS ONLINE? 
Under the Directive on General Product Safety (and 
national laws resulting from the Directive), Ben is entitled 
to receive a medicine conforming to the description 
given by the pharmaceutical company. HypnoNix must 
show the quality and the regular performances of such 
medicine and of which Ben could reasonably expect 
given the nature of the product and taking into account 
any public statements on the specifi c characteristics 
of HypnoNix made by the pharmaceutical company, 
particularly in advertising or on labelling. 
Th e Directive on General Safety Product could be useful 
to Ben, since he has a right to assume that HypnoNix 
would not present any risk or only the minimum risks 
compatible with its use. Here, HypnoNix presented severe 
side eff ects. Hence, it could be argued that HypnoNix is 
a dangerous product. In any case, the company should 
have provided Ben with enough information to enable 
him to assess the risks linked with the use of HypnoNix. 
Furthermore, if HypnoNix is industrially produced, it 
falls under the scope of the Defective Product Directive. 
HypnoNix could be regarded as a defective product if it 
does not provide the safety that a person is entitled to 
expect taking all circumstances into account. In this case, 
it is likely that HypnoNix is defective. If HypnoNix is 
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and recalled the products already supplied to consumers. 
Th ere should have been monitoring of product safety and 
collaboration with the proper authorities to avoid such 
risks. 
Furthermore, since the implant is almost certainly 
industrially produced, it likely falls under the scope of 
the Defective Product Directive. PhysioImplant could 
be regarded as a defective product if it does not provide 
the safety that a person is entitled to expect, taking all 
circumstances into account. In this case, it is likely that 
the implant is defective. If it is defective, Sophie may sue 
the producer for damages caused by personal injuries 
she suff ered as a result of using the defective product. 
She must introduce her suit within a three-year period, 
starting from the day on which she became aware, or 
should reasonably have become aware, of the damage, 
the defect, and the identity of the producer. In any case, 
the producer’s liability is limited to a ten-year period 
from the date on which the producer put the product 
into circulation. 
HOW DOES THE LAW ON IMPLANTED MEDICAL 
DEVICES PROTECT USERS OF IMPLANTED REMOTE 
MONITORING TOOLS?
Sophie employs an active implantable medical device 
administering a medicinal product. Th e medicinal product 
has to have been granted a marketing authorisation as set 
out in the Directive on Implantable Medical Devices. Th e 
medical device must comply, at least, with the essential 
requirements set out in the Annex  of the Directive 
relating to active implantable medical devices. 
In this case, as the device has compromised the health of 
Sophie, the French government must take all appropriate 
measures to withdraw the device from the market. 
Th e French government immediately must inform the 
European Commission of this measure and indicate its 
reasons. Th e information regarding such an incident has 
to be recorded and evaluated in a centralised manner. 
defective, Ben may sue the producer for damages caused 
by personal injuries. He must introduce his suit in a three-
year period starting from the day on which he became 
aware, or should reasonably have become aware, of the 
damage, the defect, and the identity of the producer. 
Finally, since HypnoNix is a medicinal product, the 
seller must comply with national rules on market 
authorisation. 
CASE VIGNETTE 2: AN IMPLANTED EHEALTH DEVICE
Sophie Sandeau was born with a congenital cardiac 
disorder that led to the implantation of her fi rst 
pacemaker at age 40. Six years later, Professor Serge 
Simon, the head cardiac surgeon at a state-of-the-
art French hospital, and his cardiologist colleague, 
Dr. Samuel Stephane, recommended that Sophie be 
equipped with the latest implantable cardiac care 
device.
Sophie now is monitored remotely using the 
PhysioImplant®, an implantable Finnish monitoring 
and dosage device. PhysioImplant provides early 
warning of cardiac failure and adjusts medication 
dosages accordingly. Measurements are taken 
automatically, and data communicated continuously 
to the cardiac monitoring centre in suburban Paris. 
Unfortunately, aft er two months, Sophie suddenly 
developed cardiac oedema and had to be hospitalised. 
Receiving too little medication because of a defect in 
the PhysioImplant system, Sophie required immediate 
hospitalisation. Fortunately, the night nurse at the 
cardiac monitoring centre acted quickly. Th e implant 
was removed and the situation improved within 
twenty-four hours.
Legal analysis
Sophie benefi ts from an implantable cardiac medical 
device with a drug distribution function, coupled with a 
tele-monitoring service. Who is liable if something goes 
wrong?
IS REMOTE CARDIAC MONITORING AN 
INFORMATION SOCIETY SERVICE COVERED BY 
ECOMMERCE LAW?
Sophie’s tele-monitoring service constitutes an 
information society service. Th e tele-monitoring service 
is covered by French law according to the principle of 
country of origin since the service provider is established 
in France and will have to respect the French law 
developed under the eCommerce Directive, as well as 
French contract law. As such, the fact that this service is 
reimbursed by social security should not infl uence the 
qualifi cation of this monitoring service as an information 
society service.
WHAT LEGAL DUTIES DOES A REMOTE MONITORING 
SERVICE PROVIDER HAVE?
Th e duties of the service provider are set out in the 
applicable law on information society services. Th ese 
duties refer mainly to the information to be provided 
to the recipient of the service. Th e service provider 
has to give to Sophie at least the following information 
concerning the tele-monitoring service: 
• Name of service provider
• Geographic address at which the service provider 
is established
• Details of the service provider, including his e-
mail address, thereby allowing rapid contact and 
communication in a direct and eff ective manner
• Where the service provider is registered in a trade 
or similar public register, the trade register in which 
the service provider is entered, and his registration 
number or equivalent means of identifi cation in that 
register
• Where the activity is subject to an authorisation 
scheme, like the provision of healthcare service or the 
particulars of the relevant supervisory authority
• Th e Value Added Tax number should be indicated
• Th e price of the tele-monitoring service should 
appear and indicate if it is inclusive of tax. 
WHO IS RESPONSIBLE IF AN IMPLANTED MEDICAL 
DEVICES MALFUNCTIONS?
Sophie suff ered a malfunction of her implantable medical 
device, which included a drug distribution function.
Under the Directive on Sale of Consumer Goods (Dir 
999/44/EC), Sophie is entitled to receive a device 
conformant to the description given by the seller. 
Th e implant must show the quality and the regular 
performances of such a device, taking into account any 
public statements on the specifi c characteristics of the 
implant made by the seller, particularly in advertising 
and on labelling. 
Th e seller of the implant will be liable for any lack of 
conformity existing at the time of the delivery. Th e 
fi nal seller is entitled to sue the previous seller of the 
product. But the remedy for the lack of conformity will 
not necessarily satisfy Sophie. Indeed, if she succeeds 
in an action, the Directive only entitles her to ask for 
a conformant product, or an appropriate reduction to 
the price of the one she has, or the cancellation of the 
contract. 
However, the Directive on General Safety Product could 
be more useful to Sophie. Th e implant should not have 
presented any risk for Sophie, or only the minimum risks 
compatible with its use. Th e implant, however, had a 
defect. Hence, it could be argued that PhysioImplant is a 
dangerous product. Th e company should have provided 
Sophie with enough information to enable her to assess 
the risks linked with the use of the implant. In this case, 
we could argue that the company should have withdrawn 
the PhysioImplant from the market, informed consumers, 
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6Trading in eHEALTH




Competition policy is one of the cornerstones of the 
internal market, which is, in itself, one of the central 
raison d’être of the European Union. Th e concept of 
the internal market is to allow European businesses to 
compete on a level playing fi eld between and across all 
the Member States of the Union. Th e role of competition 
policy and legislation is to ensure that such competition 
is allowed to prosper unhindered by anticompetitive 
practices on the part of companies, public bodies, or 
national authorities. Its central purpose is to prevent 
one or more organisations from improperly exploiting 
an economic power over weaker organisations through 
an abuse of a dominant position, as well as to prevent 
Member States’ governments from distorting competition 
through state aid. Its function, in short, is to encourage a 
market economy while still safeguarding the interests of 
European consumers.
When eHealth services are off ered on an open market 
by commercial undertakings, they will, of course, be 
governed by the rules of competition law. Th us, if a 
company off ers a diabetes monitoring service, which 
incorporates a physical device and a Web-based 
monitoring service to people suff ering from diabetes, 
directly on the open market, then such a company will 
be subject to the rules on abuse of dominant position 
and on state aid, which regulates the extent to which 
national programmes may be used to support companies 
operating in the public domain.
On the face of it, this should not cause any problems since 
an eHealth company is not necessarily any diff erent from 
a hotel group or a car manufacturer. However, the context 
in which eHealth organisations operate might make 
them signifi cantly diff erent from other organisations, not 
least because an eHealth company will, in many cases, be 
selling its services not directly to the consumer, but to a 
public health services provider who, in turn, makes the 
eHealth services available to patients and citizens in the 
course of their usual provision of care.
It should be noted that, historically and socially, the 
provision of healthcare services has been hidden from the 
purview of competition law not only because of its public 
nature, but also because healthcare generally is conceived 
of an intellectual service provided by professionals whose 
services comprise a range of skills not classifi ed into 
separate activities subject to competition. As a result, 
healthcare, historically, has not attracted the attention of 
competition lawyers to any very signifi cant extent.   
Since health services are, in most EU countries, funded 
through some form of taxation, and organised to some 
degree by public bodies, the extent to which competition 
law applies to them is somewhat unclear and may be 
limited. In particular, it is unclear in how far the rules of 
competition apply at all to publicly funded bodies, how far 
the concept of Services of General Interest apply to health 
services, and the extent to which health services are, on 
the basis of the rules on Services of General Economic 
Interest as provided for in the Treaty, exempted from the 
provisions of European competition law.
However, as healthcare services change to incorporate 
more and more technical services furnished by specialised 
providers who are not necessarily medical practitioners, 
the role of competition law will become more important 
as those providers seek to ensure that they function 
within an open market. Similarly, as more and more 
health services are purchased by private individuals, 
especially in long-term elderly care, a direct contractual 
relationship between the consumer and the health service 
provider will require that such care provision is amenable 
to the control of public competition authorities.
European Competition 
Law:  A bird’s eye view
Th e principles of free trade and competition are among 
the most important economic principles supported by 
the European Community. It is not surprising that the 
European Community has adopted a wide range of 
legislation to support competition through a legal system 
prohibiting any disloyal practices that might restrict 
competition.
Th e basis of European competition law is found in Article 
3(g) of the Treaty establishing the European Community 
(TEC). Th e article aims to establish “a system ensuring 
that competition in the internal market is not distorted.” 
In that context, the Treaty includes a number of 
articles that provide that agreements and concerted 
practices come within the jurisdiction of the European 
Community authorities if they aff ect trade between 
Member States. It is important to note that the role of 
the European Community is limited to issues aff ecting 
intra-community trade; consequently, the coexistence 
of community and national competition law sometimes 
causes the two to be applied simultaneously. 
European Community competition law is found in 
Articles 8-89 of the Treaty and falls into the following 
categories:
• Rules on undertakings (Articles 8-82)
• Rules on specifi c sectors and Services of General 
Interest (Article 86)
• Rules on state aid (Articles 87-89)
• Rules on regulation of competition
o Article 83 provides that the Commission shall 
propose directives and regulations to give force 
to Articles 8 and 82
o Articles 84 and 85 specify the respective powers 
of the Commission and the authority of Member 
States to apply Articles 8 and 82 during the 
transitional period (until the entry into force 
of the provisions adopted by the Council under 
Article 83).
 
Th e core of European competition law is found in 
the rules applying to private fi rms or undertakings in 
Articles 8 and 82. Article 8 prohibits agreements and 
concerted practices with an anticompetitive object or 
eff ect on the market, while Article 82 prohibits abuse of 
a dominant position. Article 86(2) states that the rules 
on competition also apply to public undertakings as long 
as, “the application of such rules does not obstruct the 
performance, in law or in fact, of the particular tasks 
assigned to them.”
Th e law encapsulated in the key articles above, as well 
as a wide range of case law coming from the European 
Court of Justice (ECJ), is established to allow fair and 
open competition between companies (known in the 
jurisdiction as ‘undertakings’) operating in the European 
Union. Th e purpose of the legislation is to ensure that 
trade across EU borders can take place on a level playing 
fi eld in which all may compete fairly, regardless of 
European country of origin. In order to understand the 
way in which it applies to healthcare, if at all, we must fi rst 
establish what an undertaking is, since the law applies 
only to undertakings. Th e fi rst key question for the 
purposes of healthcare providers is, therefore, whether 
they are deemed to be undertakings, and, therefore, 
subject to competition? Or are they public entities not 
subject to such regulation?
In order to clarify the current law, we must ask three key 
questions: 
• What is an undertaking and can a public body be 
classifi ed as an undertaking?
• What is a Service of General Economic Interest 
and do the rules on Services of General Economic 
Interest apply to healthcare? 
• What is state aid?
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about state aid, since many health service providers 
will be funded directly through state aid. If the state 
grants financial aid that includes special tax exemption, 
modification of credit conditions, or state contribution 
to capital financing, to an undertaking entrusted with 
delivering SGEIs, then the state must comply with the 
rules as set out in Article 87 of the Treaty.
Article 87 states that any aid granted by a Member State, 
or through state resources, in any form whatsoever, that 
distorts or threatens to distort competition by favouring 
certain undertakings or the production of certain goods 
shall, insofar as it affects trade between Member States, be 
considered as incompatible with the common market.
 
Despite the categorical tone of Article 87, the European 
Commission has the power to decide that where state 
aid has a social character and is granted to individual 
consumers (e.g., state aid to assist consumers who have 
suffered loss due to the collapse of a major industry) or 
where state aid is used to repair the damages caused by 
natural disasters, then such state aid may be considered as 
compatible with the common market. The Commission 
also may permit some specific aids.
In general, any project of state aid must be notified in 
advance to the Commission. Some state aid, however, 
in the form of public service compensation granted to 
certain undertakings entrusted with the operation of 
services of general economic interest (e.g., hospitals) are 
not considered as incompatible with the common market 
and need not be notified. 
Commission Decision of 28 November 2005 sets out the 
conditions under which state aid can be considered as 
compatible with competition rules.
8
 These conditions 
notably allow that aid of any amount granted for 
hospitals and social housing is allowable. It also provides 
that service providers that deliver a SGEI whose annual 
turnover in the last two financial years was less than 00 
million euros may be granted annual aid of up to 30 
million euros.  
If any one of these conditions is not met, then the 
payment or other benefits granted from state resources 
is a state aid for the purposes of Article 87() and subject 
to the other provisions of Article 87 and, therefore, not 
permissible.
As well as Article 87 on state aid, it should be noted that 
Article 0 of the EC Treaty requires Member States to 
take all appropriate measures to ensure the fulfilment of 
the obligations arising out of the Treaty and to abstain 
from any measure that could jeopardise the attainment 
of the objectives of this Treaty. If an undertaking is found 
to be in breach of Articles 8 or 82, a Member State can be 
found to have infringed Article 0 if the state favours or 
reinforces this anti-competitive agreement. 
WHAT IS AN ‘UNDERTAKING’ AND CAN A PUBLIC 
BODY BE CLASSIFIED AS AN UNDERTAKING?
First, it is important to note that the term undertaking 
is not defined in the EC Treaty, but its meaning has been 
set out in community case law. An undertaking includes 
any natural or legal person engaged in economic activity, 
regardless of legal status or the way it is financed. It includes 
companies, firms, businesses, partnerships, individuals 
operating as sole traders, non-profit organisations, and, 
in some circumstances, public entities that offer goods or 
services in a given market. 
The key consideration in assessing whether an entity 
is an undertaking is whether it is engaged in economic 
activity. An entity may engage in economic activity in 
relation to some of its functions but not others − thus a 
long-term care facility may be a regarded as undertaking 
economic activity for the ‘hotel’ services it provides to 
residents, since these will be contracted for on the open 
market,, but may not be acting as an undertaking in the 
healthcare it supplies if this is supplied as part of a public 
health system.
In the recent case of the Federación Española de 
Empresas de Tecnología Sanitaria (FENIN), the Court 
of First Instance of the EU found that a Spanish health 
service organisation should not be deemed to act as 
an undertaking simply because it was purchasing large 
quantities of goods or services from competitive markets. 
In the FENIN case, an association of businesses that 
market medical goods and equipment used in Spanish 
hospitals complained to the European Commission that 
several public bodies that run the Spanish national health 
system were abusing a dominant position by paying sums 
invoiced to them only after an average 300-day delay.
The European Court of Justice ruled that a purchasing 
activity is not subject to competition law if it is 
undertaken for a purely social purpose rather than as an 
economic purpose, such as a supply of goods or services 
on a market. The Court accepted the argument that, in 
this case, the Spanish hospitals operated according to 
the principle of solidarity in that they were funded from 
social security and state contributions, providing free-of-
charge services on the basis of universal cover, so they 
were found not to be engaging in economic activity. The 
Commission’s argument summarised in paragraph 24 of 
the ECJ judgment (and accepted by the Court) makes the 
point in a concise way: “[It is] the act of placing goods 
or services on a given market that characterises the 
concept of economic activity and not purchasing activity 
as such.”
 
The current situation is that most healthcare providers 
who are supplying goods or services in the execution of 
an exclusively social function; on a non-profit making 
basis; on the principle of solidarity; and where the 
entitlement to services is not dependent on the amount 
of contributions are unlikely to be legally classified as 
an undertaking conducting an economic activity. Their 
interactions with private bodies from which goods or 
services are purchased for the purposes of providing 
healthcare will not be subject to the rules on abuse of 
dominant position., A healthcare provider, however, 
operating outside those strict criteria, could well be 
classified as an undertaking and, therefore, subject to 
competition law. 
WHAT IS A SERVICE OF GENERAL ECONOMIC 
INTEREST, AND DO ITS RULES APPLY TO 
HEALTHCARE?
In the cases where a healthcare provider is classified as 
an undertaking, it might be possible for the healthcare 
provider to operate outside the rules of Articles 8 and 
82 if it has been entrusted by a public body to supply 
Services of General Economic Interest. Article 86 of the 
Treaty provides for certain types of undertakings to be 
classified as providing Services of General Economic 
Interest (SGEIs) that may be exempted from the rules of 
competition if the application of the rules would obstruct 
the performance, in law or in fact, of the particular tasks 
assigned to them. 
The first step in applying the rules on SGEIs is to 
establish that the undertaking has been duly entrusted 
to provide Services of General Economic Interest. The 
act of entrustment may be by way of legislative measures 
or regulation. An undertaking also may be entrusted 
through the grant of a concession
6
, or licence governed 
by public law.
7
Next, we must establish if the service can be classified 
as SGEI. The Treaty does not define SGEI. Instead, 
Member States define what they consider to be SGEI. 
The European Commission and Court will review the 
definition of a service as a SGEI only if they consider 
that a Member State has made a manifest error. A SGEI 
usually is a service that:
• The market does not provide or does not provide to 
the extent, or at the quality, required by the State 
• is in the general interest, i.e., it is delivered to 
the public at large and not to a specific sector of 
industry.
The service must be capable of being carried out on 
a commercial basis. Examples include public service 
broadcasting, public transport, postal services, and the 
provision of gas, electricity, and telecommunications 
services.  
Finally, any undertaking wishing to benefit from the 
exemption of competition law would have to establish 
that the application of the law to its provision of an SGEI 
would obstruct its ability to meet its duties as entrusted 
to it by a public body.
WHAT IS STATE AID?
For the health sector, it is important to think not only 
about the application of the rules on abuse of dominant 
position, and the possible exemptions of SGEIs, but also 
Case C-159/94 and C-160/94 EC Commission v the French Republic 
[1997] ECR I-05815.
Case C-393/92 Municipality of Almelo and Others v NV Energiebedrijf 
IJsselmij [1994] ECR I-1477.
Commission Decision of 28 November 2005, O.J., L 312 of 29 




••• 32 33 •••
7eHealth Trading Case Vignette
Introduction
We have, so far, provided a general overview of the 
aspects of competition and trade law having a potential 
impact on the implementation of eHealth. We now will 
use a case vignette constructed on the basis of fi ctional 
case histories to outline the way in which legislation 
might be applied in practice. Th e compilation is not a real 
case as such, but is informed by reports of real cases and 
grounded in the reality of medical practice.   
 
Soft Support Ltd., multinational soft ware specialists, 
has a division called International Medical Records 
Coordinators (IMRC) Ltd. (acquired in 2005 as the 
beginning of a healthcare strategy roll-out), which 
provides record scanning services. Founded by 
Dr. Gautam Gandhi, a practicing physician in the 
UK, IMRC’s business was based on Dr Gandhi’s 
connections between the UK and India. IMRC scans 
patient records in a mobile unit stationed outside 
British practices and then sends them to IMRC offi  ces 
in India for data entry to populate a database hosted 
on a UK Website. 
Business developed well over the fi rst eighteen months 
when suddenly, and without warning, the National 
Health Service (NHS) began to off er the same service 
to physician practices, at one-third the price. Th e NHS 
had bought out a British record-scanning company in 
order to off er the service cheaply and accelerate the 
number of records being scanned in the UK.  
Dr Gandhi’s personal fi nancial situation was 
considerably weakened. He had to make most of 
his employees redundant. IMRC and Soft Support 
wondered if the NHS entry in the scanning market, in 
this way, was legal at a European level. 
 
Legal Analysis 
Th is case raises the question as to the lawfulness of the 
NHS’ competition. 
HOW IS THE ROLE OF NATIONALISED HEALTH 
SERVICE PROVIDERS IN THE OPEN MARKET 
REGULATED?
In the case vignette, the legal question arises from the 
fact that IMRC now has to compete with the new NHS 
service off ered at one-third the price. Th e legal issue is 
whether this is an abuse of dominant position.
Th e key question is whether the NHS is classifi ed as an 
undertaking or not, since only if it is an undertaking will 
the rules on competition apply.
WHEN IS A HEALTH SERVICE PROVIDER AN 
UNDERTAKING IN TERMS OF COMPETITION LAW? 
Th e answer will depend on the activity in question. 
Legally, it is possible that the same organisation could be 
considered an undertaking for some of its activities but 
not for others.
We must examine whether the provision of record-scanning 
services performed by the NHS should be considered an 
economic activity, which would place the NHS under the 
defi nition of an undertaking as per the Treaty.
In this case, the NHS may be considered to be an 
undertaking if it is performing an economic activity that 
could be conducted by a private company or if there is 
no reason why a private company could not perform this 
activity. Th e fact that the activity is carried out by a private 
company (IMRC in this story) in certain Member States 
shows the economic character of this activity. Th erefore, 
it may be argued that the record-scanning service is an 
economic activity that the NHS is an undertaking for this 
activity, and that competition rules do apply to it for this 
activity.
WHEN MAY A HEALTH SERVICE PROVIDER 
DEROGATE FROM THE RULES ON COMPETITION?
A public entity, such as the NHS, may apply for 
derogation from the rules. Article 86.2 EC provides for 
the possibility of derogation from competition rules for 
undertakings that are entrusted with the provision of 
services of general economic interest. It states that those 
undertakings are subject to the rules contained in the 
Treaty, in particular to the rules on competition, only 
insofar as the application of such rules does not obstruct 
the performance of the particular tasks assigned to them. 
On the other hand, the development of trade must not 
be aff ected to such an extent as would be contrary to the 
interests of the community. 
Here we could argue that the application of competition 
rules does not obstruct the performance of the record-
scanning services, so derogation from competition rules 
is, therefore, not possible (i.e., competition rules apply).
HOW DO THE RULES ON ABUSE OF DOMINANT 
POSITION APPLY? 
Having established that, for this activity, the NHS is an 
undertaking, we need to examine whether it is abusing 
its dominant position when charging a lower price than 
its competitors. In order to do so, we have to identify 
the relevant product
9
 and the geographic market.
0
 Th is 
must be done on a case-by-case basis, with instruments, 
such as price eff ect analysis, to determine the impact on 
consumers.
To assess dominance, two elements generally are 
analysed: the type of entry barriers and the importance 
of market shares. Some very important market shares 
may be considered as a dominant position (e.g., 75% or 
more). A typical case of a dominant position is when an 
undertaking has a signifi cant market share and there are 
high entry barriers. Th e existence of a dominant position is 
not forbidden, as such. It is only the abuse of this position 
that is unlawful. Considering this, the application of an 
unfair price could be qualifi ed as an abuse of dominant 
position if the low price is not justifi ed. In this case, the 
NHS would have to argue in court that the low price it 
proposes is justifi able. 
BUT IS HEALTHCARE NOT DIFFERENT -  IS IT NOT 
CONTROLLED AT MEMBER STATE LEVEL?
It must be remembered that community action, including 
competition rules, have to respect the Member States’ 
responsibilities for the organisation and provision of 
health services and medical care, as per Article 52 of 
the Treaty. Th us the NHS might provide the counter-
argument that in the interests of maintaining an effi  cient 
and eff ective public health system, its functioning in this 
particular issue (record management) should be taken 
outside the scope of EU competition law because to apply 
the rules would compromise its ability to meet the health 
needs of the people it serves.
A relevant product market comprises all products and/or services 
that are regarded as interchangeable or substitutable by the 
consumer by reason of the products’ characteristics, its price, and 
intended use.
A relevant geographic market comprises the area in which the 
concerned firms are involved in the supply of products or services, 




“This is a fi ctional case. No inference should be drawn about the business practices of the National Health Service in the United Kingdom. To be best of the authors’ 
knowledge no case such as this has ever occurred in the UK” 
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8Conclusions
Through the case vignettes described in this report we have 
seen that eHealth products and services raise numerous 
new legal questions. Among these, the “Legally eHealth” 
report has looked in particular data protection, liability and 
consumer protection, and some aspects of competition law 
as being the most signifi cant issues at this time.
A reading of the report will confi rm that generally 
European law provides the Member States with a 
signifi cant number of harmonised answers and solutions 
to integrate eHealth tools into daily medical practice. 
However, presentation of the study described in this 
report at various conferences and meetings has revealed 
that there is a lack of legal certainty amongst health actors 
necessary to support wide implantation of eHealth.
Accordingly it is recommended that actions are taken 
at European and Member State level addressing the 
following issues: 
A defi nition of duties and rights of all actors involved 
in an eHealth system, including clarifi cation of the 
rules on data protection to ensure a proper balancing 
between the patient’s right to privacy and the need for 
adequate data sharing in a modern eHealth enabled 
healthcare system.
A formal standardisation of the interoperability of the 
infrastructure and of eHealth products and services. 
A formal standardisation of the security requirements 
for both the infrastructure and the eHealth products 
and services. 
An assessment of the impact of competition legislation 
on the uptake of eHealth applications, with a view to 
addressing such legislation to encourage the growth of 
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RoHS Directive 2002/95/EC of the European Parliament 
and of the Council of 27 January 2003 on the restriction 
of the use of certain hazardous substances in electrical 
and electronic equipment. 
Legal Sources Concerning 
Health-care
Council Directive 90/385/EEC of 20 June 990 on the 
approximation of the laws of the Member States relating 
to active implantable medical devices
Directive 98/79/EC on in vitro diagnostic medical 
devices
Directive 200/83/EC of the European Parliament and 
of the Council of 6 November 200 on the Community 
code relating to medicinal products for human use
Council Directive 93/42/EEC of 4 June 993 concerning 
medical devices
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Community providing exceptions on the application of 
the competition rules for undertakings entrusted with 
the operation of general economic interest
Article 87 of the Treaty establishing the European 
Community prohibiting direct or indirect state aid 
that may distort competition by favouring certain 
undertakings
Council Regulation (EC) No 39/2004 of 20 January 
2004 on the control of concentrations between 
undertakings (the EC Merger Regulation)
Commission decision of 28 November 2005 on the 
application of Article 86(2) of the EC Treaty to State aid 
in the form of public service compensation granted to 
certain undertakings entrusted with the operation of 
services of general economic interest, O.J., L 32 of 29 















Communication from the European Commission 
on social services of general interest in the European 
Union, SEC 2006/56.
Commission communication on ‘Professional Services’ 
of 5 September 2005, COM 2005/405.
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994, Case C-364/92
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LEGAL SOURCES ON 
DATA PROTECTION
Directive 95/46/CE of the European Parliament and 
of the Council of 25 October 995 on the protection of 
individuals with regards to the processing of personal 
data and on the free movement of such data
Directive 2002/58/CE of the European Parliament and 
of the Council of 2 July 2002 concerning the processing 
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of publicly available electronic communications services 
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Directive 2002/58/EC
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individuals with regard to the processing of personal 
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Protocols
Recommendation (97) 5 of the Committee of Ministers 
to Member States on the protection of medical data, 
adopted on 3 February 997
Recommendation (83) 0 of the Committee of Ministers 
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Recommendation (97) 8 of the Committee of 
Ministers of Members States concerning the protection 
of personal data collected and processed for statistical 
purposes, adopted on 30 September 997
Recommendation (99) 5 of the Committee of Ministers 
of Members States for the protection of privacy on the 
Internet, adopted on 23 February 999
Communication 2004 (356) from the Commission to 
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of the regions, “eHealth - Making Healthcare Better 
for European Citizens: An Action Plan for a European 
eHealth Area”
Some opinions or recommendations made by the Data 
Protection Working Party
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ON PRODUCT AND 
SERVICES LIABILITY
Legal Sources Concerning 
Information Society
Directive 999/93/EC on a Community framework for 
electronic signatures
Directive 2000/3/EC of the European Parliament and 
of the Council of 8 June 2000 on certain legal aspects 
of information society services, in particular electronic 
commerce, in the Internal Market (‘Directive on 
electronic commerce’)
Legal Sources Concerning 
Business and Consumer 
Protection
Directive 2005/29/EC of the European Parliament and of 
the Council of  May 2005 concerning unfair business-
to-consumer commercial practices in the internal 
market (Unfair Commercial Practices Directive). 
This Directive replaces the business-to-consumer 
rules in the misleading and comparative advertising 
Directives (Directive 84/450/EEC of 0 September 984 
relating to the approximation of the laws, regulations 
and administrative provisions of the Member States 
concerning misleading advertising as modified by 
Directive 97/55/EC of European Parliament and of 
the Council of 6 October 997 concerning misleading 
advertising so as to include comparative advertising). 
Those two Directives still apply to business-to-business 
activities.
Directive 97/7/EC on the protection of consumers in 
respect of distance contracts
Directive 999/44/EC of the European Parliament and 
of the Council of 25 May 999 on certain aspects of the 
sale of consumer goods and associated guarantees
Directive 200/95/EC of the European Parliament and 
of the Council of 3 December 200 on general product 
safety
European Convention on products liability in regard 
to personal injury and death of 27 January 977 (NB: 
Council of Europe)
Council Directive 85/374/EEC of 25 July 985 on 
the approximation of the laws, regulations and 
administrative provisions of the Member States 
concerning liability for defective products as modified 
by Directive 999/34/EC of the European Parliament 
and of the Council of 0 May 999 amending Council 
Directive 85/374/EEC on the approximation of the 
laws, regulations and administrative provisions of 
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